[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"choroidal-neovascularization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:choroidal-neovascularization":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,61,92,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100631122","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-003-100631122",false,"NCT07496567","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-003)","A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201\u002FMK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)","TORRONTES","The main inclusion criteria include but are not limited to the following:\n\n* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)\n* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment\n\nThe main exclusion criteria include but are not limited to the following\n\n* Has uncontrolled blood pressure at screening\n* History of any prior macular laser photocoagulation in the study eye\n* History of uveitis in either eye\n* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study\n* Has uncontrolled glaucoma in the study eye\n* Active retinal disease other than the condition under investigation in the study eye\n* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye","ALL","50 Years",{"count":20,"type":21},960,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).\n\nAvailable standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.\n\nThe goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.",[28,29,30,31],"Macular Degeneration","Age-Related Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2026-04-15",{"date":40,"type":21},"2028-07-31",{"name":42,"class":43},"EyeBiotech Ltd.","INDUSTRY",48,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":14,"acronym":50,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":26,"conditions":53,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100626791","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-002-100626791","NCT07440225","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-002)","MALBEC",{"count":20,"type":21},[24,25],[28,29,30,31],{"date":35,"type":36},{"date":56,"type":36},"2026-03-27",{"date":58,"type":21},"2028-06-30",{"name":42,"class":43},71,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100607380","phase-4-long-term-efficacy-of-faricimab-using-a-treat-and-extend-regimen-for-type-3-macular-neovascularization-100607380","NCT07187804","Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","Inclusion Criteria:\n\n\\[General\\]\n\n* Signed Informed Consent Form\n* Age \\> 50 years at the time of signing Informed Consent Form\n* Participants who are able to comply with the study protocol, in the investigator's judgment\n* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception (will be defined in details in protocol)\n\n\\[Ocular\\]\n\n* BCVA that is equal or higher than 24 Early Treatment Diabetic Retinopathy Study letters on Screening Day\u002F Day 0.\n* Confirmed diagnosis, by the investigator, of symptomatic type 3 neovascularization based on sufficiently clear ocular media and adequate pupillary dilatation allowing acquisition of good quality retinal images for confirmation.\n* Treatment naive participants\n\nExclusion Criteria:\n\n\\[General\\]\n\n* Treatment with investigational therapy (device, drug, or traditional medicine with the exception of vitamins and minerals) within 3 months prior to initiation of study treatment on study Day 1\n* Any major illness or major surgical procedure within 1 month before screening\n* Active cancer within the 12 months prior to study Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of \\\u003C 6 (Grade Group of 1) and a stable prostate-specific antigen for \\>12 months\n* Continuous use of any medications and treatments (which will be indicated in the Prohibited Therapy section in protocol)\n* Systemic treatment for suspected or active systemic infection on study Day 1\n* Uncontrolled blood pressure, defined as systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 100 mmHg while the participant is at rest on study Day 1\n* History of stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to study Day 1\n* History of other disease, metabolic dysfunction, physical examination finding, or historical or current clinical laboratory findings giving reasonable suspicion of a condition that contraindicates the use of the investigational drug or that might affect interpretation of the results of the study or renders the participant at high risk for treatment complications in the opinion of the investigator\n* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the faricimab injection, study-related procedure preparations (including fluorescein and indocyanine green dyes), dilating drops, or any of the anesthetic and antimicrobial preparations used by a participant during the study\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the final dose of faricimab\n\n\\[Ocular\\]\n\n* Significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, or fundus photography.\n* Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n\nAny ocular or periocular infection within the last 2 weeks prior to Screening in either eye.\n\n* Any history of uveitis in either eye.\n* Presence of definite chorioretional anastomosis\n* Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible macular neovascularization.)\n* Scar or fibrosis, making up \\> 50% of total lesion in the study eye.\n* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.\n* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.\n* History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye.\n* Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 76 week study period.\n* Prior vitrectomy in the study eye\n* Any history of macular hole of stage 2 and above in the study eye.\n* Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as it's unlikely to interfere with the injection.\n* Prior trabeculectomy or other filtration surgery in the study eye.\n* Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye.\n* Active intraocular inflammation in either eye.\n* Active ocular or periocular infection in either eye.\n* Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of an yttrium aluminum garnet \\[YAG\\] posterior capsulotomy) in the study eye.",{"count":68,"type":21},30,[70],"PHASE4","Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision.\n\nFaricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal perfusion. While anti-vascular endothelial growth factor (VEGF) agents suppress neovascularization, prolonged VEGF blockade may impair choriocapillaris health. Ang-2 inhibition, by promoting Tie2 activation and vascular stability, may protect choriocapillaris and reduce widespread retinal edema and hemorrhages observed in type 3 MNV.\n\nFinally, while treat-and-extend is widely used in practice, existing trials (TENAYA, LUCERNE) applied broader extension intervals than typically used clinically. In type 3 MNV, where undertreatment carries severe consequences, a more stringent faricimab-based treat-and-extend regimen with 2-week interval adjustments warrants investigation.",[73,30,74],"Age-related Macular Degeneration (ARMD)","Anti-vascular Endothelial Growth Factor",[76,77,78,79,80],"Age-related macular degeneration","Type 3 macular neovascularization","Retinal angiomatous proliferation","Faricimab","Treat and extend","NOT_YET_RECRUITING","2025-09-19",{"date":84,"type":36},"2025-09-23",{"date":84,"type":21},{"date":87,"type":21},"2028-09-22",{"name":89,"class":90},"Kim's Eye Hospital","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":91},"100593125","effect-of-video-viewing-on-intravitreal-injection-experience-100593125","NCT07002372","Effect of Video Viewing on Intravitreal Injection Experience","Impact of Procedural Video Viewing on Patients Undergoing Intravitreal Anti-VEGF Injections","Inclusion Criteria:\n\n* Patients who are receiving their first intravitreal injection of anti-VEGF medication due to retinal diseases\n* Mentally competent, and able to communicate without barriers\n* Willing to voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* History of previous eye surgery\n* Best-corrected visual acuity in the better eye worse than 0.3\n* The target eye is complicated with neovascular glaucoma.","18 Years",{"count":101,"type":21},182,[103],"NA","Study Objective The goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing intravitreal anti-VEGF injections.\n\nKey Research Questions\n\n1. Can viewing the procedural video prior to treatment reduce the rate and\u002For area of subconjunctival hemorrhage?\n2. Can the video improve the patient experience, specifically by reducing anxiety levels and increasing satisfaction with the treatment process?\n\nStudy Design Participants will be randomly assigned to either an intervention group, who will watch an educational video explaining the injection procedure, or a control group, who will not view the video.\n\nAll participants will complete the State-Trait Anxiety Inventory-State (STAI-S) questionnaire both before and after treatment to assess changes in anxiety levels.",[106,107,30,108,109],"Age Related Macular Degeneration","Diabetic Retinopathy","Retinal Vein Occlusion","Cystoid Macular Edema","2025-06-01",{"date":112,"type":36},"2025-06-03",{"date":114,"type":36},"2025-05-05",{"date":116,"type":21},"2025-10-05",{"name":118,"class":90},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":91},"100586642","an-interpretable-fundus-diseases-report-generating-system-based-on-weakly-labelings-100586642","NCT06918028","An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings","To Construct an Interpretable Multi-modal Report Generating System For Fundus Diseases Based On Weakly Labelings","Inclusion Criteria:\n\n* Disease group: All multimodal fundus examination images containing fundus lesions, examined from January 2011 to December 2023, including fundus photography, as well as OCT, OCTA, FFA, ICGA, B-ultrasound and corresponding imaging reports. Images could be either clear or unclear, reports are either complete or incomplete.\n* Normal group: All multimodal fundus examination images without fundus lesions, examined from January 2011 to December 2023, including fundus photography, as well as OCT, OCTA, FFA, ICGA, B-ultrasound and corresponding imaging reports. Images could be either clear or unclear, reports are either complete or incomplete.\n\nExclusion Criteria:\n\n* Disease group: 1. The image has serious quality problems; 2. The diagnostic report lacks key information.\n* Normal group: 1. The image has serious quality problems; 2. The diagnostic report lacks key information.",true,{"count":128,"type":21},9999,"OBSERVATIONAL","To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly labeled training data. Construct an interpretable feature fusion network for the clinical and imaging features of fundus lesions, and we hope to extract new imaging markers that can predict the occurrence and progression of various fundus lesions at an early stage, and ultimately verify them in real clinical data, further providing possible directions for exploring the molecular mechanisms of refractory fundus lesions, and may also provide new ideas for the precise prevention and treatment of fundus lesions.",[132,133,134,107,106,30],"Retinal Diseases","Choroidal Disease","Pathological Myopia","2025-04-05",{"date":137,"type":36},"2025-04-09",{"date":139,"type":21},"2025-05",{"date":141,"type":21},"2026-12",{"name":143,"class":90},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]